# Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma

## TL;DR

This review discusses how liposomal nanoparticles can improve the treatment of multiple myeloma by enhancing drug delivery and reducing side effects.

## Contribution

The paper provides a comprehensive overview of recent advances in targeted liposomal nanotherapeutics for multiple myeloma.

## Key findings

- Liposomal nanoparticles show potential in overcoming drug resistance and reducing side effects in MM treatment.
- Targeted drug delivery systems improve therapeutic outcomes by enabling controlled drug release.
- Challenges remain in optimizing targeting methods and nanoparticle design for clinical applications.

## Abstract

Multiple myeloma (MM) remains a challenging type of hematological cancer, characterized by the growth and accumulation of clonal plasma cells within the bone marrow. Current traditional therapies, mainly conventional chemotherapeutics, demonstrate limited therapeutic capacity due to considerable side effects and drug resistance. In this direction, liposomal nanotherapeutics have emerged as a promising new strategy in cancer therapy, holding great potential to address the chemical and biological constraints of existing anticancer treatments. This review presents a summary of the latest developments in the application of targeted liposomal nanoparticles as a drug carrier system for the management of MM. Furthermore, it explores the challenges linked to creating efficient drug delivery systems, targeting methods, and the processes involved in controlled drug release.

This review summarizes recent advances in liposomal nanoparticle-based drug delivery systems aimed at improving therapeutic outcomes in multiple myeloma.